Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapyLEDERGERBER, Bruno; MOCROFT, Amanda; LUNDGREN, Jens D et al.The New England journal of medicine. 2001, Vol 344, Num 3, pp 168-174, issn 0028-4793Article

Lopinavir/Ritonavir Pharmacokinetics, Efficacy, and Safety in HIV and Hepatitis B or C Coinfected Adults Without Symptoms of Hepatic ImpairmentKHAYKIN, Pavel; KOTZERKE, Peter; STEPHAN, Christoph et al.Therapeutic drug monitoring. 2014, Vol 36, Num 2, pp 192-201, issn 0163-4356, 10 p.Article

Prognostic Value of Vitamin D Level for All-cause Mortality, and Association With Inflammatory Markers, in HIV-infected PersonsSHEPHERD, Leah; SOUBERBIELLE, Jean-Claude; KIRK, Ole et al.The Journal of infectious diseases. 2014, Vol 210, Num 2, pp 234-243, issn 0022-1899, 10 p.Article

Immune Response after Two Doses of the Novel Split Virion, Adjuvanted Pandemic H1N1 Influenza A Vaccine in HIV-1―Infected PatientsBICKEL, Markus; VON HENTIG, Nils; ALLWINN, Regina et al.Clinical infectious diseases. 2011, Vol 52, Num 1, pp 122-127, issn 1058-4838, 6 p.Article

Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patientsWALKER, Ulrich A; BICKEL, Markus; VOLKSBECK, Severine I. Lütke et al.Journal of acquired immune deficiency syndromes (1999). 2002, Vol 29, Num 2, pp 117-121, issn 1525-4135Article

Safe interruption of Maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapyKIRK, Ole; REISS, Peter; UBERTI-FOPPA, Caterina et al.Annals of internal medicine. 2002, Vol 137, Num 4, pp 239-250, issn 0003-4819Article

HIV-related neuropathology, 1985 to 1999: Rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapyNEUENBURG, Jutta K; BRODT, Hans R; HERNDIER, Brian G et al.Journal of acquired immune deficiency syndromes (1999). 2002, Vol 31, Num 2, pp 171-177, issn 1525-4135, 7 p.Article

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durationsSOLIMAN, Elsayed Z; LUNDGREN, Jens D; NEATON, James D et al.AIDS (London). 2011, Vol 25, Num 3, pp 367-377, issn 0269-9370, 11 p.Article

Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy settingHABERL, Annette; MOESCH, Manfred; NISIUS, Gabriele et al.European journal of clinical pharmacology. 2010, Vol 66, Num 4, pp 375-381, issn 0031-6970, 7 p.Article

Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1 N1 influenza vaccine in HIV-1-infected patientsBICKEL, Markus; WIETERS, Imke; ALLWINN, Regina et al.AIDS (London). 2010, Vol 24, Num 9, issn 0269-9370, F31-F35Article

Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophyBICKEL, Markus; ZANGOS, Stephan; LUTZ, Thomas et al.Scandinavian journal of infectious diseases. 2008, Vol 40, Num 1, pp 36-39, issn 0036-5548, 4 p.Article

Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosisBICKEL, Markus; STEPHAN, Christoph; ROTTMANN, Carsten et al.Scandinavian journal of infectious diseases. 2005, Vol 37, Num 6-7, pp 520-522, issn 0036-5548, 3 p.Article

Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrityJUNG, Oliver; BICKEL, Markus; DITTING, Tilmann et al.Nephrology, dialysis, transplantation (Print). 2004, Vol 19, Num 9, pp 2250-2258, issn 0931-0509, 9 p.Article

A case of severe CMV-colitis in an HIV positive patient despite moderate immunodeficiencyWOLF, Timo; BICKEL, Markus; FAUST, Dominik et al.Scandinavian journal of infectious diseases. 2003, Vol 35, Num 11-12, pp 904-906, issn 0036-5548, 3 p.Article

Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppressionPHILLIPS, Andrew N; STASZEWSKI, Schlomo; MILLER, Veronica et al.The Journal of infectious diseases. 2002, Vol 186, Num 8, pp 1086-1091, issn 0022-1899, 6 p.Article

Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individualsPHILLIPS, Andrew N; MILLER, Veronica; SABIN, Caroline et al.AIDS (London). 2001, Vol 15, Num 18, pp 2379-2384, issn 0269-9370Article

Nephropathy in Illicit Drug Abusers: A Postmortem AnalysisBUETTNER, Maike; TOENNES, Stefan W; BUETTNER, Stefan et al.American journal of kidney diseases. 2014, Vol 63, Num 6, pp 945-953, issn 0272-6386, 9 p.Article

Comparison of Drug Resistance Scores for Tipranavir in Protease Inhibitor-Naïve Patients Infected with HIV-1 B and Non-B SubtypesSTÜRMER, Martin; STEPHAN, Christoph; GUTE, Peter et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 11, pp 5362-5366, issn 0066-4804, 5 p.Article

The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypesSIERRA, Saleta; LÜBKE, Nadine; WALTER, Hauke et al.Medical microbiology and immunology. 2011, Vol 200, Num 4, pp 225-232, issn 0300-8584, 8 p.Article

Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravirBICKEL, Markus; ANADOL, Evrim; BECHSTEIN, Wolf Otto et al.Journal of antimicrobial chemotherapy (Print). 2010, Vol 65, Num 5, pp 999-1004, issn 0305-7453, 6 p.Article

Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virusSTEPHAN, Christoph; BERGER, Annemarie; CARLEBACH, Amina et al.Journal of antimicrobial chemotherapy (Print). 2005, Vol 56, Num 6, pp 1087-1093, issn 0305-7453, 7 p.Article